Ebola Sudan Therapeutic

Ebola Sudan Therapeutic

BioFactura is developing an Ebola Sudan therapeutic in close collaboration with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID). While several mAb cocktails specific for Zaire virus have been developed and tested, research dedicated for Sudan virus-specific antibody immunotherapy development is currently lacking. There exists a tremendous void in the Ebola virus therapeutic arsenal in terms of Sudan virus-specific countermeasures, leaving us vulnerable to Sudan virus infection with no way of actively treating or managing outbreaks. This is concerning considering Ebola virus outbreaks in the past five years have consisted of two Zaire virus outbreaks including the recent large outbreak in West Africa, and three independent Sudan virus outbreaks. The prevalence of Sudan virus seems to be on the rise, yet a concerted effort to develop Sudan virus-specific countermeasures is nonexistent. Our MCM is aimed at addressing this void and providing an effective antibody-based immunotherapies against Sudan virus, similar to antibody-based immunotherapies that have proven efficacious against Zaire virus. Addition of this countermeasure to U.S. stockpiles would provide a scalable, safe, and effective drug to treat and protect both the warfighter and civilian.